Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV

  • STATUS
    Not Recruiting
  • End date
    May 1, 2023
  • participants needed
    175
  • sponsor
    Gilead Sciences
Updated on 5 May 2021
Investigator
Gilead Study Team
Primary Contact
East Carolina University, The Brody School of Medicine (2.5 mi away) Contact
+68 other location

Summary

The primary objective of this study is to evaluate the efficacy of lenacapavir (formerly GS-6207) containing regimens in people living with HIV (PLWH).

Details
Condition HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection, HIV-1-infection
Treatment F/TAF, TAF, B/F/TAF, BIC, Oral GS-6207, Subcutaneous GS-6207, Oral Lenacapavir, Subcutaneous Lenacapavir
Clinical Study IdentifierNCT04143594
SponsorGilead Sciences
Last Modified on5 May 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note